)
Overview
<ul>
<li>Biopharmaceutical firm’s Q4 collaboration revenue fell yr/yr</li>
<li>Company reported Q4 net loss of $32.4 mln</li>
<li>Operating expenses decreased 30% in 2025 compared to 2024</li>
</ul>
Outlook
<ul>
<li>Company projects operating runway through year-end 2027 with $205 mln in cash</li>
<li>Fate Therapeutics to provide clinical updates in H2 2026</li>
<li>Company plans Phase 2 trial in lupus nephritis</li>
</ul>
Result Drivers
<ul>
<li>OUTPATIENT TREATMENT - FT819 off-the-shelf CAR T-cell therapy enabled outpatient treatment, expanding access and reducing hospital stays</li>
<li>CANCER THERAPY SUCCESS - FT836 showed significant tumor reduction in colorectal cancer without conditioning chemotherapy, highlighting early activity</li>
<li>COST REDUCTION - Company plans a 30% reduction in operating expenses in 2025 compared to 2024, supporting financial runway through 2027 Company press release:</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
<h3>Q4 $1.37</h3>
Collabor mln
ation
Revenue
Q4 Net -$32.37
Income mln
Q4 Basic -$0.27
<h3>EPS</h3>
<h3>Q4 -$34.72</h3>
Income mln
from
Operatio
ns
<h3>Q4 $36.09</h3>
Operatin mln
g
Expenses
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 6 “strong buy” or “buy”, 6 “hold” and no “sell” or “strong sell”</li>
<li>The average consensus recommendation for the biotechnology &amp; medical research peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for Fate Therapeutics Inc is $5.00, about 237.8% above its February 25 closing price of $1.48 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</li>
</ul>

IBBQ

FATE

SBIO

Reuters

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

Fate Therap

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Fate Therapeutics reports lower Q4 collaboration revenue